3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Infections
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
COVID-19
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Adenocarcinoma Of Esophagus
1
Interventions
Trimethoprim, Sulfamethoxazole Drug Combination
9
Ciprofloxacin
7
gamma-Globulins
3
Voriconazole
3
Fluconazole
3
Daptomycin
3
Antibiotic Prophylaxis
3
Amoxicillin-Potassium Clavulanate Combination
3
Whole-Body Irradiation
2
Vancomycin
2
Trimethoprim
2
Sulfamethoxazole
2
Saline Solution
2
Ribavirin
2
Peripheral Blood Stem Cell Transplantation
2
Pentetic Acid
2
Melphalan
2
Itraconazole
2
Immunoglobulins, Intravenous
2
Fosfomycin
2
Ethanol
2
Cyclophosphamide
2
Cefazolin
2
Caspofungin
2
ziprasidone
1
tocilizumab
1
telavancin
1
telaprevir
1
talquetamab
1
soybean oil, phospholipid emulsion
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Infections
×
monalizumab
×
Clear all
NCT04333914
2022-09-30
IMMUNONCOVID
Centre Leon Berard
Phase 2
Completed
19 enrolled